Key result
SGLT2 inhibitor benefits in diabetes are overstated and primarily driven by a diuretic mechanism.
Why the study?
There is a need to clarify the true efficacy and mode of action of SGLT2 inhibitors in diabetic patients, distinguishing validated outcomes from observational or undemonstrated endpoints.
Do SGLT2 inhibitors improve cardiovascular and renal outcomes in diabetic patients?
Population
Diabetic patients from eight SGLT2i Cardiovascular Outcomes trials
Comparison
SGLT2 inhibitors versus standard care or placebo
Design
Comprehensive review of medical agencies' analyses and CVOTs
Authors
Loading...
Challenges overstated CV benefits of SGLT2 inhibitors in diabetes; leaves open whether diuretic effects predominate in prospective trials.
Do SGLT2 inhibitors improve cardiovascular and renal outcomes in diabetic patients?
This review challenges the widespread belief in the long-term morbidity and mortality benefits of SGLT2 inhibitors in diabetic patients, highlighting their primary diuretic mechanism and waning antidiabetic efficacy.
Cesar Lam (2023) conducted a review in Type 2 diabetes (n=57,000). SGLT2 inhibitors vs. Placebo was evaluated. SGLT2 inhibitors' cardiovascular benefits in diabetic patients are largely overstated and mostly based on undemonstrated endpoints, with their efficacy primarily driven by a diuretic mode of action.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: